by Madaline Spencer | May 21, 2026
A recent clinical study analysis of Oxbryta (voxelotor), globally withdrawn in 2024, was submitted to the FDA with the intent of getting voxelotor back on the market. Sickle cell disease (SCD) is a disorder in which red blood cells become “sickle”-shaped and can not...
by Madaline Spencer | May 20, 2026
Hans Katzberg, MD, Professor of Neurology at the University of Toronto and Neurologist at Toronto General Hospital, discusses post hoc analyses from the ADHERE clinical trial in chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a...
by Madaline Spencer | May 19, 2026
Angela Zhu, MD, is an Ophthalmologist and Clinical Assistant Professor, Pediatric & Adult Cornea/Cataract/External Diseases, at Bascom Palmer Eye Institute in Miami. In this interview with CheckRare, Dr. Zhu describes some of the key features of plasminogen...
by Madaline Spencer | May 18, 2026
Naji Gehchan, MD, MBA, Chief Medical and Development Officer at Kyverna Therapeutics, discusses primary analysis of KYV-101 for the treatment of stiff person syndrome (SPS). SPS is a progressive neuromuscular condition caused by increased muscle activity...
by Madaline Spencer | May 15, 2026
The US Food and Drug Administration (FDA) has granted accelerated approval to Beqalzi (sonrotoclax) for the treatment of adults with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine...
